---

Diagnostic Algorithm & Provisional Diagnosis

Clinical Summary

---

Provisional Diagnosis

PCDH19-Related Epilepsy (Protocadherin-19 Clustering Epilepsy)

• Affects females only (brothers are classically unaffected carriers)
• Intractable focal/multifocal seizures beginning in early childhood
• Corpus callosum anomalies and cerebral asymmetry/hemiatrophy on MRI
• Developmental delay and intellectual disability
• Autosomal dominant with X-linked inheritance pattern — males are unaffected mosaic carriers

---

Differential Diagnoses

---

Diagnostic Algorithm

Step 1 — Confirm seizure semiology & EEG characterization
         ↓
         Prolonged video-EEG monitoring
         → Confirm right focal onset
         → Look for multifocal or bilateral independent foci
         → Ictal EEG pattern in PCDH19: focal/multifocal, often frontotemporal

Step 2 — Neuroimaging workup
         ↓
         MRI brain (3T, epilepsy protocol)
         → Confirm right hemiatrophy (cortical thinning? volume loss?)
         → Characterize corpus callosum defect: agenesis / hypoplasia / dysgenesis?
         → Assess hippocampal formation
         → DTI tractography (callosal fiber integrity)

Step 3 — Metabolic & Biochemical screening
         ↓
         Serum: lactate, pyruvate, ammonia, amino acids
         Urine: organic acids, GAGs, oligosaccharides
         CSF: glucose, lactate, amino acids, neurotransmitters
         → Rule out mitochondrial disorder, organic acidemias

Step 4 — Genetic Testing (PRIORITY)
         ↓
         Trio whole exome sequencing (child + parents)
         Or targeted gene panel:
         → PCDH19 (Xq22.1) — first priority
         → SCN1A (Dravet), CDKL5, ARX, MECP2, WDR45
         Chromosomal microarray — for structural variants / deletions
         Skewed X-inactivation studies in females

Step 5 — Family screening
         ↓
         Both sisters: full neurological evaluation + EEG + MRI
         Brother: PCDH19 sequencing (confirm carrier status)
         Parents: PCDH19 sequencing (identify de novo vs. inherited)

Step 6 — Ophthalmologic evaluation
         ↓
         Fundoscopy → rule out chorioretinal lacunae (Aicardi syndrome)
         OCT retinal imaging

Step 7 — Neuropsychological assessment
         ↓
         Developmental/IQ testing
         Autism spectrum screening (PCDH19 has ~50% autism comorbidity)
         Behavioral phenotyping

---

Why PCDH19 Stands Out

• The gene is on the X chromosome (Xq22.1)
• Hemizygous males (one copy, all cells affected) are unaffected — uniform expression causes no cellular interference
• Heterozygous females (mosaic expression: some cells PCDH19+, some PCDH19−) have cellular interference between two populations of neurons → epilepsy
• Homozygous/hemizygous affected males are rare and represent a separate mechanism

PCDH19 Key Features

• Seizure onset: 6 months to 3 years
• Cluster seizures (brief, frequent, in clusters over days) that may be fever-triggered early
• Often right-dominant or lateralized focal EEG
• Corpus callosum hypoplasia/dysgenesis reported in subset
• Cerebral asymmetry and cortical dysplasia reported
• Comorbidities: autism (~50%), intellectual disability, behavioral disorders
• Treatment: Bromides, clobazam, valproate — avoid sodium channel blockers (like carbamazepine, lamotrigine) as they may worsen

---

Management Outline (Pending Diagnosis)

1. Acute seizure control: Benzodiazepines for cluster abort; avoid triggering factors (fever)
2. AED selection:
   • Valproate + clobazam as first-line combination
   • Bromides (potassium bromide): particularly effective in PCDH19
   • Fenfluramine: FDA-approved for seizure reduction in PCDH19 epilepsy (2022 indication expanded)
   • Avoid: phenytoin, carbamazepine, lamotrigine (sodium channel blockers may aggravate)
3. Ketogenic diet: Consider for intractable cases
4. Genetic counseling: For family — recurrence risk assessment
5. Developmental therapies: Speech, occupational, physiotherapy
6. Multidisciplinary team: Pediatric neurology, genetics, neuropsychology, ophthalmology

---

Summary

Provisional diagnosis: PCDH19-Related Clustering Epilepsy (high probability)

The combination of intractable right focal seizures in a young girl, brain structural anomalies (right hemiatrophy + corpus callosum defects), developmental delay, and crucially female-specific familial pattern with unaffected brother constitutes a near-classic presentation. Aicardi syndrome is the important alternate to exclude (requires ophthalmology + confirming corpus callosum agenesis pattern).

First priority investigation: PCDH19 gene sequencing (trio) + MRI epilepsy protocol + prolonged video-EEG.

---

Differential Diagnosis with Physical Findings

Clinical Profile Recap

---

1. PCDH19 Clustering Epilepsy (Top Diagnosis)

Physical Findings

---

2. Aicardi Syndrome (Must Exclude)

Physical Findings

Key differentiator from PCDH19: chorioretinal lacunae on fundoscopy + vertebral/rib anomalies + infantile (not late infancy/toddler) onset

---

3. Rasmussen Encephalitis

Physical Findings

---

4. Dravet Syndrome (SCN1A)

Physical Findings

---

5. Focal Cortical Dysplasia (FCD)

Physical Findings

---

6. Hemimegalencephaly

Physical Findings

---

Physical Examination Approach: What to Look For

General
  ├─ Dysmorphic features? → Aicardi (yes) vs PCDH19 (no)
  ├─ Growth parameters (height, weight, OFC) → microcephaly?

Skin (full body under Wood's lamp)
  ├─ Ash-leaf macules → Tuberous sclerosis
  ├─ Hypomelanosis of Ito (Blaschko lines) → Hemimegalencephaly
  ├─ Epidermal nevus → ENES syndrome
  ├─ Incontinentia pigmenti whorls → X-linked dominant
  └─ Normal → PCDH19, Dravet

Eyes (CRITICAL)
  ├─ Fundoscopy
  │    ├─ Chorioretinal lacunae → AICARDI (pathognomonic)
  │    ├─ Coloboma → Aicardi
  │    └─ Normal → PCDH19
  └─ Visual fields → hemianopia (Rasmussen, FCD)

Neurological
  ├─ Tone: hypotonia (PCDH19, Aicardi, Dravet) vs spasticity (Rasmussen)
  ├─ DTRs: asymmetric hyperreflexia → structural lesion / Rasmussen
  ├─ Power: hemiparesis → Rasmussen, FCD, Hemimegalencephaly
  ├─ Babinski sign: present → structural / Rasmussen
  └─ Cerebellar signs: ataxia → Dravet (older children)

Spine / Skeleton
  ├─ Vertebral anomalies (hemivertebrae, rib fusions) → Aicardi

Behavior
  └─ Autistic features, hyperactivity → PCDH19

---

Summary Comparison Table

---